Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status

Ben A. Lopman,1 Tarak Trivedi,1 Yosselin Vicuña,3,4 Veronica Costantini,1,2 Nikail Collins,1 Nicole Gregoricus,1 Umesh Parashar,1 Carlos Sandoval,3,4 Nely Broncano,3,4 Maritza Vaca,3,4 Martha E. Chico,3,4 Jan Vinje,1 and Philip J. Cooper3,4,5

1Division of Viral Diseases, Centers for Disease Control and Prevention, and 2Department of Pediatrics, Emory University, Atlanta, Georgia; 3Laboratorio de Investigaciones FEPIS, Quinindé, and 4Centro de Investigaciones en Enfermedades Infecciosas, Pontificia Universidad Católica del Ecuador, Quito, Ecuador; and 5Institute of Infection and Immunity, St George’s University of London, United Kingdom

Background. Although norovirus is the most common cause of gastroenteritis, there are few data on the community incidence of infection/disease or the patterns of acquired immunity or innate resistance to norovirus.

Methods. We followed a community-based birth cohort of 194 children in Ecuador with the aim to estimate (1) the incidence of norovirus gastroenteritis from birth to age 3 years, (2) the protective effect of norovirus infection against subsequent infection/disease, and (3) the association of infection and disease with FUT2 secretor status.

Results. Over the 3-year period, we detected a mean of 2.26 diarrheal episodes per child (range, 0–12 episodes). Norovirus was detected in 260 samples (18%) but was not found more frequently in diarrheal samples (79 of 438 [18%]), compared with diarrhea-free samples (181 of 1016 [18%]; P = .919). A total of 66% of children had at least 1 norovirus infection during the first 3 years of life, and 40% of children had 2 infections. Previous norovirus infections were not associated with the risk of subsequent infection. All genogroup II, genotype 4 (GII.4) infections were among secretor-positive children (P < .001), but higher rates of non-GII.4 infections were found in secretor-negative children (relative risk, 0.56; P = .029).

Conclusions. GII.4 infections were uniquely detected in secretor-positive children, while non-GII.4 infections were more often found in secretor-negative children.

Keywords. norovirus; immunity; histo-blood group antigen; cohort study; incidence.

Norovirus is increasingly recognized as the most common etiology of diarrheal disease in all age groups and the second most common cause of severe disease in young children. Norovirus is associated with approximately 18% of gastroenteritis cases worldwide, and this proportion is similar across the age range [1]. In some developed countries, including the United States, where infant vaccination has reduced the incidence of rotavirus gastroenteritis, norovirus remains the most common cause of pediatric gastroenteritis in patients brought to medical care [2].

Noroviruses are a genetically diverse group of single-stranded RNA viruses and can be divided into genogroups, of which viruses from genogroup I (GI), genogroup II (GII), and genogroup IV (GIV) infect humans. Immunity is not lifelong, as infection, reinfection, and disease occur throughout life. Challenge studies conducted since the 1970s have indicated that protection against infection and disease is primarily against the same genotype [3]. A recent birth cohort study of Peruvian children confirmed this, as GII infections were protective against subsequent GII infection and disease and reinfection with the same genotype was uncommon [4].
In addition to acquired immunity, there is also a human genetic component to norovirus susceptibility. Noroviruses use glycans of the ABH and Lewis histo-blood group antigen (HBGA) family for attachment to their target cells [5]. Expression of HBGAs is catalyzed by α1,2 fucosyltransferase encoded by the gene encoding α(1,2) fucosyltransferase (FUT2). Individuals with ≥1 functional FUT2 allele and, thus expression of FUT2 enzyme are called secretor-positive individuals. Homozygous individuals with a nonsense mutation (FUT2−/−) are called secretor-negative individuals and represent up to 20% of the European population [6]. Most data on susceptibility to norovirus infection pertain to the prototype Norwalk strain (GI, genotype 1 [GI1]) used in challenge studies, with limited observational data demonstrating that expression of HBGAs is associated with strain-specific susceptibility to norovirus infection [7–10]. Although most data from field studies suggest a pattern of secretor-dependent susceptibility to norovirus infection [7, 8, 11–13], other studies have shown that secretor-negative individuals can also be infected [14–19]. Several studies have also demonstrated that norovirus strains differ in their ability to bind HBGAs [20–23]. For example, most GII, genotype 4 (GII4) viruses bind to secretor-positive individuals from all ABO blood groups [14]; GI1 strongly binds secretor-positive individuals from blood group A, O, and AB [8]; whereas GI, genotype 8 (GI8) binds saliva from secretor-positive and secretor-negative individuals [23].

While norovirus is frequently detected in stool samples from patients with diarrhea, the virus can also be detected in healthy individuals. Overall, detection rates are approximately 8% among healthy controls [1], but in some studies, mainly involving children from low-income countries, norovirus has been nearly as prevalent, and sometimes more so, in controls than in cases [24, 25]. Cohort studies may be better suited to understand the natural history of norovirus infection and shedding in healthy controls, especially in children in developing countries [24].

In light of the progress of norovirus vaccine development [26], it is becoming critically important to characterize the incidence of endemic, community-acquired norovirus and the acquisition of natural immunity against norovirus infection and diarrhea. In this study, we followed a community-based birth cohort in a rural district in Ecuador with the aim to estimate (1) the incidence of norovirus gastroenteritis from birth to 3 years of age, (2) the protective effect of norovirus infection against subsequent infection and disease, and (3) the association of infection and disease with FUT2 secretor status.

METHODS

Ethics Statement
The study was approved by institutional review boards of Pontificia Universidad Católica del Ecuador (Quito, Ecuador) and the Centers for Disease Control and Prevention (Atlanta, Georgia). Written informed consent was obtained from each child’s parent or guardian.

Study Design, Recruitment, and Data Collection
The study was conducted in Quinindé, a town in Esmeraldas Province in tropical, coastal Ecuador. A diarrhea surveillance cohort of 194 children was recruited between March and December 2009 from within a birth cohort, the ECUAVIDA cohort, which is described in detail elsewhere [27]. Briefly, the cohort of 2404 children from the District of Quinindé was recruited around the time of birth at the public hospital (Hospital Padre Alberto Buffoni [HPAB]) in Quinindé between November 2006 and December 2009. A subset of the larger cohort was included in a group monitored under diarrhea surveillance: children entering the birth cohort between March 2009 and December 2009 who lived within the municipal boundaries of Quinindé were enrolled for the surveillance study and were followed up to 3 years of age. Inclusion criteria into the surveillance study were as follows: (1) healthy and aged <14 days, (2) maternal stool sample availability, (3) maternal age of ≥17 years, and (4) residence in Quinindé. Routine telephone calls were made twice weekly to mothers to determine whether the child in the surveillance sample had diarrhea, and medical records of visits to the cohort pediatric clinic at HPAB were collected. All families were advised on the importance of surveillance and were asked to report all cases of diarrhea to the clinic or directly to the study coordinator in Quinindé. During each telephone call, the mother or caregiver was also asked about any illness at present; respiratory symptoms, fever, diarrhea, or other signs or symptoms in the child or other members of the household were recorded. If diarrhea was reported, the family was asked to take the child to the clinic the same day for assessment of severity, treatment, and collection of a stool specimen. If this was not possible, a physician visited the child’s house for evaluation and sample collection either the same day or the next day. Stool collection from asymptomatic children occurred during routine home visits at ages 7, 13, 24, and 36 months and during routine clinic visits at ages 3, 18, and 30 months. A child was considered asymptomatic if they did not have diarrhea for at least 2 weeks before the routine home visit. During home visits at ages 7, 13, 24, and 36 months, child length/height (measured using infantometers/stadiometers) and weight (measured using digital pediatric scales) were recorded.

Norovirus Testing
All collected stool samples were aliquoted into 2-mL tubes at the FEIPS laboratory in Quinindé and stored at 4°C. RNA extraction was done using the Qiagen QIAamp Viral RNA Mini Kit, and extracted RNA was stored at ~20°C prior to analysis. Real-time reverse transcription polymerase chain reaction (RT-qPCR) was used to detect GI and GII norovirus RNA [28]. All cycle threshold (Ct) values of <40 were considered
positive; we also repeated all analysis with Ct cutoffs of <35 for GI viruses or <37 for GII viruses. The latter approach reduced the overall rates of infection but did not affect any of the patterns or observed associations (data not shown). Positive samples were genotyped by sequence analysis [29].

Definitions
A diarrhea sample was defined as a stool sample obtained from a child who had ≥3 liquid or semiliquid stools in 24 hours, with a time of collection of <14 days before the telephone call or consultation with the clinic/hospital. When a child presented to the clinic with diarrhea, stool samples and clinical data were collected after physician evaluation. Norovirus diarrhea was considered an episode of diarrhea in which norovirus RNA was detected in stool by RT-qPCR. Asymptomatic norovirus infection was defined as a stool sample from an asymptomatic child in which norovirus was detected.

Blood Group and Secretor Genotyping
ABO blood group determination of capillary blood samples was done by agglutination with standard antisera. To ascertain secretor status, saliva samples were collected from children >3 years of age into Oragene Discover OG575 kits (DNA Genotek, Canada), and DNA was extracted by following the manufacturer’s instructions. Secretor status genotyping was determined by PCR amplification and pyrosequencing of FUT2 at nucleotide 428 (G>A) as previously described [6].

Statistical Analysis
The prevalence and 95% confidence intervals (CIs) of norovirus infection among diarrhea cases and asymptomatic control samples was estimated according to a binomial distribution. We calculated the cumulative incidence of diarrhea, norovirus infection, and disease by Kaplan–Meier survival analysis. Cumulative incidence estimates were generated at 12, 24, and 36 month of age. The follow-up time for an individual child was divided according to the number of previous infections. For example, the period between birth and first infection was identified as 0 previous infections and the period between first infection and second infection was identified as 1 previous infection. The number of previous infections was then modeled as a time-varying covariate. To examine the association of previous infection episodes, individual-level, and family-level characteristics with norovirus infection and disease risk, we fitted multi-level mixed-effect Poisson regression models. The individual child (with multiple observation periods) was considered the level for the random effect under the assumption of independent covariance. We calculated P values for associations with norovirus infection and disease rates and genogroup-specific infection rates by the Wald test. All regression analyses were controlled for age (in 6-month intervals up to 1 year and in yearly intervals thereafter) and sex.

RESULTS

Recruitment and Characteristics of Surveillance Cohort
A total of 194 children were recruited and followed up in the surveillance cohort. The 194 children were followed for 206 658 person-days. The range of follow-up was 211–1305 days, with >90% of children followed for at least 2 years. The numbers of children followed to at least 6 months, 1 year, 2 years, and 3 years of age were 194 (100%), 193 (>99%), 183 (94%), and 135 (70%), respectively. A total of 151 children (77%) were recruited on the first day of life, and all were recruited before day 14 of age. Relevant characteristics of study children, their mothers, and their living environment are provided in Table 1. All children lived in an urban environment in the town of Quinindé and tended to

Table 1. Characteristics of Surveillance Birth Cohort (N = 194)

| Characteristic                  | Individuals, Percentage (No.) |
|--------------------------------|--------------------------------|
| Mother                         |                                |
| Age, y, median                 | 24                             |
| Education level                |                                |
| Incomplete primary             | 11 (21)                        |
| Complete primary               | 59 (114)                       |
| Complete secondary             | 30 (59)                        |
| Household                      |                                |
| Socioeconomic status           |                                |
| Low                            | 17 (33)                        |
| Medium                        | 33 (65)                        |
| High                           | 50 (96)                        |
| No. of other children          |                                |
| 0                              | 29 (56)                        |
| 1                              | 26 (50)                        |
| ≥2                             | 45 (88)                        |
| Child                          |                                |
| Sex                            |                                |
| Female                        | 54 (105)                       |
| Male                          | 46 (89)                        |
| Birth weight, g                |                                |
| <3300                          | 47 (92)                        |
| ≥3300                          | 53 (102)                       |
| Breast-feeding duration, mo    |                                |
| 0–6                            | 16 (31)                        |
| 7–12                           | 39 (75)                        |
| ≥13                            | 45 (85)                        |
| Secretor status                |                                |
| Positive                       | 88 (157)                       |
| Negative                       | 12 (21)                        |
| Blood group                    |                                |
| O                              | 62 (111)                       |
| A                              | 20 (35)                        |
| B                              | 16 (29)                        |
| AB                             | 2 (3)                          |

Data on breast-feeding duration were missing for 3 children, and data on secretor status and blood group were missing for 16 children.
be of higher socioeconomic level than the cohort in general (50% were defined as being in the high socioeconomic tertile). A high proportion of children lived in a household with at least 2 other children of households (88 [45%]) and had a flushing toilet (122 [63%]), but relatively few had access to potable piped water (25 [13%]). Blood group and secretor genotypes were determined at 3 years of age in 178 children (92%; Table 1): most children (111 [62%]) were blood group O, and 158 (88%) were secretor positive. The proportions, by FUT2 genotype, were as follows: SeSe (homozygote secretor-positive children), 79 (44%); Se^428s^428 (heterozygote secretor-negative children): 21 (12%).

Over the 3-year study period, 1454 stool samples were collected, of which 438 (30%) were collected during an episode of acute diarrhea, while 1016 (70%) samples were collected from children without diarrhea symptoms for at least 14 days. There was a median of 7 samples (range, 1–20 samples) collected per child. There were no major demographic differences in children with ≥7 samples collected, compared with those with <7 samples collected, with the exception of children with older mothers, who had fewer samples collected (P = .008).

**Diarrhea and Norovirus Infections**

Over the 3-year period, we detected a mean (±SD) of 2.26 ± 2.30 diarrheal cases per child (range, 0–12 cases): 44 children (23%) had 0 episodes of diarrhea, 85 (44%) had 1–2 episodes, 50 (26%) had 3–5 episodes, and 15 (8%) had >5 episodes. The cumulative incidence of diarrhea in the surveillance cohort, by number of episodes over the 36 months of follow-up, is shown in Figure 1A.

Norovirus was detected in 260 samples (18%) but was not found more frequently in diarrheal samples (79 of 438 [18%]) than in routine samples (181 of 1016 [18%]; P = .919). This pattern did not appear to differ by age (Figure 2). However, when norovirus was detected, viral loads (based on Ct values) were higher in diarrheal samples (median Ct value, 28.02), compared with routine samples (median Ct value, 32.2; P = .005 by the Wilcoxon rank sum test; data not shown).

Sixty-six percent of children had at least 1 documented infection (with or without symptoms) with norovirus during the first 3 years of life, 40% of children had 2 infections, but few (16%) had >2 infections (Figure 1B). At least 1 episode of norovirus-associated diarrhea was observed in 30% of children (59), but relatively few (10%) had >1 episode (Figure 1C). Overall, norovirus infection and disease was detected at rates of 51 cases per
### Table 2. Association Between Previous Infections, Sociodemographic Characteristics, and Host Characteristics and Norovirus Infection and Disease Risk

| Variable                                   | Infection | Disease |
|--------------------------------------------|-----------|---------|
|                                            | No. Rate | RR (95% CI) | P Value | No. Rate | RR (95% CI) | P Value |
| No. of previous norovirus infections       |          |           |         |          |           |         |
| 0                                         | 130      | 43.5      | Reference | 40      | 13.4      | Reference |
| 1                                         | 79       | 71.5      | 1.01 (.51–1.99) | .972    | 30       | 27.1      | 1.88 (1.11–3.21) | .019 |
| ≥2                                        | 43       | 51.9      | 0.82 (.26–2.52) | .422    | 13       | 15.7      | 1.19 (.50–2.90) | .692 |
| No. of previous genogroup I infections    |          |           |         |          |           |         |
| 0                                         | 190      | 47.6      | Reference | 62      | 15.5      | Reference |
| ≥1                                        | 62       | 66.6      | 1.21 (.90–1.63) | .204    | 21       | 22.6      | 1.51 (.84–2.74) | .170 |
| No. of previous genogroup II infections   |          |           |         |          |           |         |
| 0                                         | 161      | 47.7      | Reference | 52      | 15.4      | Reference |
| ≥1                                        | 91       | 58.7      | 0.92 (.60–1.42) | .721    | 31       | 20.0      | 1.24 (.71–2.18) | .450 |
| Age, mo                                   |          |           |         |          |           |         |
| 0–5                                       | 5        | 5.2       | Reference | 3       | 3.1       | Reference |
| 6–11                                      | 73       | 75.7      | 14.65 (5.92–36.24) | <.001   | 34       | 35.3      | 11.34 (3.49–37.01) | <.001 |
| 12–23                                     | 117      | 63.8      | 12.35 (5.05–30.23) | <.001   | 38       | 20.7      | 6.66 (2.06–21.59) | .002 |
| 24–36                                     | 57       | 49.1      | 9.50 (3.81–23.71) | <.001   | 8        | 6.9       | 2.16 (.57–8.17) | .243 |
| Sex                                       |          |           |         |          |           |         |
| Male                                      | 106      | 46.1      | Reference | 28      | 12.2      | Reference |
| Female                                    | 146      | 55.5      | 1.20 (.93–1.55) | .153    | 55       | 20.9      | 1.68 (1.03–2.77) | .039 |
| Socioeconomic status                      |          |           |         |          |           |         |
| Low                                       | 32       | 39.1      | Reference | 10      | 12.2      | Reference |
| Medium                                    | 78       | 46.4      | 1.17 (.78–1.78) | .440    | 25       | 14.9      | 1.23 (1.56–2.70) | .611 |
| High                                      | 142      | 58.5      | 1.47 (1.00–2.17) | .049    | 48       | 19.8      | 1.60 (.77–3.33) | .208 |
| No. of other children in household        |          |           |         |          |           |         |
| 0                                         | 72       | 51.3      | Reference | 21      | 15.0      | Reference |
| 1                                         | 58       | 45.5      | 0.89 (.63–1.27) | .537    | 19       | 14.9      | 1.04 (1.51–1.95) | .902 |
| ≥2                                        | 122      | 54.3      | 1.02 (.76–1.38) | .885    | 43       | 19.1      | 1.21 (1.72–2.77) | .505 |
| Maternal education level                  |          |           |         |          |           |         |
| Incomplete primary                        | 19       | 36.2      | Reference | 6       | 11.4      | Reference |
| Complete primary                          | 150      | 51.3      | 1.34 (.83–2.19) | .235    | 55       | 18.8      | 1.50 (1.60–3.75) | .386 |
| Complete secondary                        | 83       | 56.1      | 1.52 (1.91–2.52) | .106    | 22       | 14.9      | 1.24 (1.47–3.31) | .655 |
| Season                                    |          |           |         |          |           |         |
| Dry (July to Nov)                         | 132      | 54.1      | Reference | 32      | 13.1      | Reference |
| Wet (Dec to Jun)                          | 120      | 48.2      | 0.72 (.56–.93) | .012    | 51       | 20.5      | 1.36 (.87–2.16) | .179 |
| Secretor status                           |          |           |         |          |           |         |
| Negative                                  | 24       | 45.9      | Reference | 8       | 15.3      | Reference |
| Positive                                  | 216      | 52.8      | 1.15 (.75–1.77) | .522    | 71       | 17.4      | 1.20 (.53–2.71) | .655 |
| Secretor genotype                         |          |           |         |          |           |         |
| Not applicable                            | 24       | 45.9      | Reference | 8       | 15.3      | Reference |
| Heterozygous                              | 104      | 50.4      | 1.09 (.70–1.71) | .703    | 27       | 13.1      | 0.89 (.37–2.09) | .793 |
| Homozygous                                | 112      | 55.2      | 1.21 (.77–1.90) | .402    | 44       | 21.7      | 1.51 (.66–3.47) | .328 |
| Blood group                               |          |           |         |          |           |         |
| O                                         | 149      | 52.1      | Reference | 47      | 16.4      | Reference |
| A                                         | 47       | 52.5      | 0.99 (.71–1.40) | .992    | 10       | 11.2      | 0.65 (0.31–1.36) | .259 |
| B                                         | 40       | 51.4      | 0.96 (0.67–1.37) | .806    | 21       | 27.0      | 1.59 (0.89–2.86) | .116 |
| A/B                                       | 4        | 50.8      | 1.07 (.38–2.97) | .900    | 1        | 12.5      | 1.06 (1.12–9.15) | .952 |

Abbreviations: CI, confidence interval; RR, relative risk.

a Per 100 person-years.
b All models include age and sex as controlling covariates.
c Data are for secretor-negative children.
100 person-years (95% CI, 45–58) and 17 cases per 100 person-years (95% CI, 14–21), respectively.

Age was an important determinant of the risk of norovirus infections (Table 2): the peak incidence of norovirus infections, 76 infections per 100 person-years, was observed between 6 and 11 months of age, declining to 9.5 infections per 100 person-years at 24–36 months of age (Table 2). The associations between risk of norovirus infection or norovirus diarrhea and previous norovirus infections, sociodemographic factors, and individual characteristics are shown in Table 2. The only factor associated with the incidence of norovirus infections was season, with higher rates of infection during the dry months of July through November (P = .012). Previous norovirus infections were not significantly associated with the risk of subsequent norovirus infection.

The incidence of norovirus diarrhea was strongly dependent on age, with a peak at 6–11 months of age of 35.3 episodes per 100 person-years. Norovirus diarrhea incidence was more frequent among females (P = .039) but was not significantly associated with secretor status or genotype. Having one previously documented norovirus infection was positively associated with the risk of norovirus diarrhea, although the same effect was not observed for ≥2 previous infections.

### Norovirus Genotype Distribution

A total of 154 samples (61%) were GII positive, 85 (34%) were GI positive, and 13 (5.2%) had GI/GII mixed infections. Factors associated with incidence of infection with GI and GII norovirus are shown in Tables 3 and 4. There was a tendency for higher risk among secretor-positive children for GII infection (although the difference was not statistically significant) but no apparent association with GI, after control for age and sex. Similarly, previous norovirus infections, regardless of genogroup, were not associated with the incidence of subsequent infections.

#### Table 3. Association Between Previous Infections, Sociodemographic Characteristics, and Host Characteristics and Norovirus Genogroup I and II Infection Risk

| Variable                        | Genogroup I | Genogroup II |
|---------------------------------|-------------|--------------|
|                                 | No. | Rate<sup>a</sup> | RR (95% CI)<sup>b</sup> | P Value | No. | Rate<sup>a</sup> | RR (95% CI)<sup>b</sup> | P Value |
| No. of previous norovirus infection |     |                |                      |         |     |                |                      |         |
| 0                               | 47  | 15.7          | Reference           | .074    | 90  | 30.1          | Reference           | .432    |
| 1                               | 36  | 31.7          | 1.54 (.95–2.47)     | .074    | 49  | 44.3          | 1.15 (.80–1.65)     | .730    |
| ≥2                              | 16  | 19.3          | 1.01 (.45–2.24)     | .973    | 28  | 33.7          | 0.92 (.58–1.46)     | .730    |
| No. of previous genogroup I infection |     |                |                      |         |     |                |                      |         |
| 0                               | 75  | 18.8          | Reference           | .623    | 124 | 31.0          | Reference           | .139    |
| ≥1                              | 23  | 24.7          | 1.12 (.69–1.83)     | .623    | 43  | 46.2          | 1.31 (.91–1.89)     | .584    |
| No. of previous genogroup II infection |     |                |                      |         |     |                |                      |         |
| 0                               | 61  | 18.1          | Reference           | .731    | 110 | 32.6          | Reference           | .584    |
| ≥1                              | 37  | 23.8          | 1.07 (.70–1.67)     | .731    | 57  | 37.8          | 0.81 (.39–1.69)     | .584    |
| Season                          |     |                |                      |         |     |                |                      |         |
| Dry (July to Nov)               | 37  | 15.1          | Reference           | .204    | 99  | 40.6          | Reference           | .37     |
| Wet (Dec to Jun)                | 61  | 24.5          | 1.38 (.86–1.98)     | .204    | 68  | 27.3          | 0.55 (.40–.75)      | <.001   |
| Secretor status                 |     |                |                      |         |     |                |                      |         |
| Negative                        | 12  | 22.9          | Reference           | .658    | 12  | 22.9          | Reference           | .658    |
| Positive                        | 82  | 20.1          | 0.87 (.46–1.65)     | .658    | 147 | 35.9          | 1.56 (.86–2.82)     | .658    |
| Secretor genotype               |     |                |                      |         |     |                |                      |         |
| Not applicable<sup>c</sup>      | 12  | 22.9          | Reference           | .12     | 12  | 22.9          | Reference           | .12     |
| Heterozygous                    | 41  | 19.8          | 0.86 (.45–1.65)     | .658    | 69  | 33.5          | 1.45 (.79–2.68)     | .232    |
| Homozygous                      | 41  | 20.2          | 0.88 (.46–1.69)     | .702    | 78  | 38.5          | 1.68 (.92–3.09)     | .094    |
| Blood group                     |     |                |                      |         |     |                |                      |         |
| O                               | 60  | 21.0          | Reference           | .742    | 95  | 33.2          | Reference           | .742    |
| A                               | 17  | 18.9          | 0.90 (.52–1.54)     | .692    | 32  | 35.7          | 1.07 (.71–1.59)     | .753    |
| B                               | 15  | 11.6          | 0.90 (.51–1.59)     | .826    | 29  | 37.2          | 1.10 (.72–1.69)     | .045    |
| A/B                             | 2   | 6.2           | 1.27 (.30–5.37)     | .742    | 3   | 37.6          | 1.22 (.38–3.90)     | .737    |

Abbreviations: CI, confidence interval; RR, relative risk.

<sup>a</sup> Per 100 person-years.

<sup>b</sup> All models include age and sex as controlling covariates.

<sup>c</sup> Data are for secretor-negative children.
infection. The only factor associated with infection was the reduced incidence of GII infections observed during the wet season (December through June; \( P < .001 \)). An association in the opposite direction was observed for GI, but this was nonsignificant.

We were able to determine the genotype for 106 samples (Figure 3). The most common genotype was GII.4 (27 infections [25%]), followed by GI.1 (20 [19%]), GI.3 (9 [8%]), GI.2 (11 [10%]), and a tentative new GII genotype (GII.23; 6 [6%]). We observed 12 GI/GII mixed infections (11%), including 4 due to GII.4 (4%). Among the GII.4-positive samples (including those from mixed infections), the following variants were observed: New Orleans 2009, 21 samples; Den Haag 2006, 5; Sydney 2012, 4; and Osaka 2008, 1. The genotype distribution among diarrheal stools and healthy stools was similar.

All 27 GII.4 single infections and all 4 coinfections that were positive for GII.4 were in secretor-positive children (relative risk [RR], undetermined; \( P < .001 \) for both comparisons; Tables 3 and 4). We observed a nonsignificantly lower rate of GII infection (excluding GII.4; RR, 0.69; 95% CI, 0.31–1.15) and GI infection (RR, 0.63; 95% CI, 0.31–1.15) among secretor-positive children. However, when combining all non-GII.4 noroviruses, the rates of infection were significantly lower among secretor-positive children, compared with secretor-negative children (RR, 0.56; 95% CI, 0.34–0.94; \( P = .023 \)). We also detected a tentative new GII genotype (GII.23); all 6 positive

### Table 4. Norovirus Genotype–Specific Rates of Infection for Secretor-Negative and Secretor-Positive Children

| Variable                                      | Secretor Negative | Secretor Positive | RR (95% CI)\(^{b}\) | \( P \) Values |
|-----------------------------------------------|-------------------|-------------------|----------------------|---------------|
| GI                                            | 4                 | 18                | 0.61 (0.21–1.70)     | .342          |
| GII (excluding GII.4)                         | 7                 | 38                | 0.63 (0.31–1.15)     | .358          |
| GII.1                                         | 5                 | 17                | 0.69 (0.15–1.21)     | .111          |
| GI/GII mixed (excluding GII.4)                | 0                 | 6                 | Undetermined         | <.001         |
| GII.1 (single infections)                     | 0                 | 27                | Undetermined         | <.001         |
| GI/GII mixed (including GII.4)                | 0                 | 31                | Undetermined         | <.001         |
| Non-GII.4 (combined)                          | 14                | 59                | 0.56 (0.34–0.94)     | .029          |
| GII.4 (single infections)                     | 0                 | 4                 | 0.19 (0.05–0.80)     | .024          |
| GII.4 (including GI mixed)                    | 0                 | 0                 | Undetermined         | <.001         |

Abbreviations: CI, confidence interval; GI, genogroup I; GII, genogroup II; GI.1, genogroup II, genotype 1; GII.4, genogroup 2, genotype 4; RR, relative risk.

\(^{a}\) Per 100 person-years.

\(^{b}\) All models include age and sex as controlling covariates.

---

**Figure 3.** Norovirus genotype distribution of infections in secretor-negative (A) and secretor-positive (B) children. Abbreviation: G, genogroup.
samples were detected in secretor-positive children (RR, undermined; \( P < .001 \)).

**DISCUSSION**

With 60% of children having at least 1 infection (symptomatic or asymptomatic) and 30% at least 1 norovirus-associated diarrhea episode within the first 3 years of life, this study confirms the high incidence of norovirus infection in children that has been found by many studies worldwide \([1, 4, 30]\). Our results were not consistent with the notion of acquired immunity to norovirus, whereby each infection would be expected to provide a degree of protection against the next. Nor did we find evidence that immunity is genogroup specific: rates of GI or GII infections did not decrease following previous infection(s) with the same genogroup. Overall, the rates of norovirus infection and disease were similar among secretor-positive and secretor-negative children, but the genotypes causing infections differed markedly. All GII.4 infections were among secretor-positive individuals.

Our findings contrast, to some extent, with those of a recent birth cohort study from neighboring Peru \([4]\). Saito et al found roughly similar rates of norovirus infection and disease that we found, but they observed a modest reduction in infection and disease rates in children with previous infections. Saito et al tested routine samples more frequently, at least in the first year of life, when monthly samples were tested, which means they had a more complete capture of asymptomatic infections. Field workers also visited each household twice weekly, so they may have had more-complete capture of diarrhea episodes.

Our study is consistent with volunteer challenge studies and observational studies demonstrating that secretor-negative individuals have near-complete resistance to GII.4 infection \([15, 31]\), as well as to GI.I. infection \([8, 10]\) and a new GII genotype described in this study. GII.4 noroviruses can also infect secretor-negative individuals, suggesting a lack of complete resistance to disease \([16]\). This is in agreement with a recent study that suggests that most recent GII.4 variants are able to bind Lewis glycans from secretor-negative individuals \([14]\). Challenge studies with norovirus GI.II showed that 33% of secretor-negative individuals were infected \([17]\). Moreover, other studies have shown that GI.II noroviruses can infect independently of secretor status of the host \([18, 19]\). Resistance to infection among secretor-negative individuals has been demonstrated mainly for GI.I and GII.4 \([8, 10, 15]\), with an apparent lack of association for GI.II \([31]\) or GI.II \([11]\); few data exist for other genotypes.

An unexpected finding of our study was that the rate of non-GII.4 infection was nearly double among secretor-negative children. Therefore, overall, rates of disease were the nearly same among secretor-positive and secretor-negative children. We are not aware of any previous data suggesting a heightened risk of infection for secretor-negative individuals. It is possible that non-GII.4 viruses bind to currently unknown ligands in secretor-negative individuals. Another hypothesis is that GII.4 infection confers some degree of heterotypic immunity to subsequent infection with non-GII.4 viruses. However, our sample size was too small to test this hypothesis.

Birth cohort studies can be instrumental in gaining understanding of the acquisition of immunity to childhood infections \([32, 33]\), and we have advocated for such study designs for norovirus \([34]\). So why did we not observe patterns consistent with the acquisition of immunity? A weakness of our study was the relatively infrequent collection of routine stool samples from healthy children. We collected a routine stool sample approximately every 6 months. With duration of shedding typically lasting <1 month, more-frequent sampling would result in detection of more infections, so it is likely that substantial numbers of asymptomatic infections were missed. Although there were extended periods when some children were temporarily lost to follow-up, excluding these periods from analyses did not appreciably change our results (data not shown), but this leaves open the possibility that substantial numbers of symptomatic infections were missed. Underascertainment in our cohort is a possible explanation for our negative findings: we measured a diarrhea incidence of <1 episode per child-year, compared with an estimate of 4.0 episodes per child-year based on a systematic review of 29 studies from the Americas \([35]\).

In summary, our study suggests a high incidence of norovirus infection and disease in Ecuadorian children, but we did not find clear evidence for acquired immunity. Secretor-negative individuals were completely protected against GII.4 viruses, as well as a tentative new GI genotype, and they had higher rates of infection with non-GII viruses. Taken together, these findings point to a more complicated relationship between host genetics and pathogen than previous described, with GII.4 being more common and other viruses being less common among secretor-positive individuals.

Future studies may require more-frequent sampling of asymptomatic infections, longer follow-up, and larger sample sizes to improve our understanding of the acquisition of immunity and empirical estimates of the duration of protection, if such protection truly exists. Because our understanding of norovirus immunity comes mainly from controlled clinical trials rather than from observational studies in the field, it is possible that natural infection may differ in a number of ways, including exposure frequency, patient age, exposure dose, and norovirus genotype. Much larger studies will be required to explore norovirus genotype–specific immunity. As such, further observational field studies are necessary to understand both naturally acquired and vaccine-acquired immunity.

**Notes**

**Acknowledgments.** We thank the ECUAVIDA study team, for their dedicated work; the cohort mothers and children, for their enthusiastic participation; and the Ecuadorian Ministry of Public Health and the director
and staff of the Hospital Padre Alberto Buffoni, Quinindé, Esmeraldas, for their support. The study was supported by Wellcome Trust grants 07/4679/Z/04/Z, and 088862/Z/09/Z.

Disclaimer. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Financial support. This work was supported by the Wellcome Trust (grant 088862/Z/09/Z), the CDC, and the American Society of Tropical Medicine and Hygiene (Benjamin H. Kean Travel Fellowship in Tropical Medicine to T. T.).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14:725–30.
2. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. New Engl J Med 2013; 368:1121–30.
3. Wyatt RG, Dolin R, Blacklow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974; 129:709–14.
4. Saito M, Goel-Apaza S, Espetia S, et al. Multiple norovirus infections in a birth cohort in a Peruvian perurban community. Clin Infect Dis 2014; 58:483–91.
5. Tan M, Jiang X. Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Rev Mol Med 2014; 16:e5.
6. Kindberg E, Hejdeman B, Bratt G, et al. A nonsense mutation (428G>A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS 2006; 20:685–9.
7. Hutson AM, Airauf F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol 2005; 77:116–20.
8. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. NatMed 2003; 9:548–53.
9. Larsson MM, Rydell GE, Grahn A, et al. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis 2006; 194:1422–7.
10. Lindesmith L, Moe C, LePendu J, Freijinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005; 79:2900–9.
11. Thoren M, Grahn A, Hedlund KO, et al. A homozygous nonsense mutation (428G>A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol 2005; 79:15351–5.
12. Tan M, Jin M, Xie H, Duan Z, Jiang X, Fang Z. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection. J Med Virol 2008; 80:1296–301.
13. Kindberg E, Akerlind B, Johnsen C, et al. Host genetic resistance to symptomatic norovirus (GGII4) infections in Denmark. J Clin Microbiol 2007; 45:2720–2.
14. de Rougemont A, Ruvoen-Clouet N, Simon B, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol 2011; 85:4057–70.
15. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386–93.
16. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PloS One 2009; 4:e5593.
17. Lindesmith L, Moe C, Lepundu J, Freijinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005; 79:2900–9.
18. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis 2010; 16:81–7.
19. Rockx BH, Vennema H, Hoebe CJ, Duizer E, Koopmans MP. Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis 2005; 191:749–54.
20. Huang P, Farkas T, Zhong W, et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005; 79:6714–22.
21. Marionneau S, Airauf F, Bovin NV, Le Penu J, Ruvoen-Clouet N. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J Infect Dis 2005; 192:1071–7.
22. Rydell GE, Nilsson J, Rodriguez-Diaz J, et al. Human noroviruses recognize sialyl Lewis x neoglycoprotein. Glycobiology 2009; 19:309–20.
23. Shirato H, Ogawa S, Ito H, et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigen 1 for binding. J virol 2008; 82:10576–67.
24. Lopman B, Simmons K, Gambhir M, Vinje J, Parashar U. Epidemiologic implications of asymptomatic reinfection: a mathematical modeling study of norovirus. Am J Epidemiol 2014; 179:507–12.
25. Kolhoff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209–22.
26. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178–87.
27. Cooper PJ, Chico ME, Platts-Mills TA, Rodrigues LC, Strachan DP, Barreto ML. Cohort Profile: The Ecuador Life (ECUAVIDA) study in Esmeraldas Province, Ecuador. Int J Epidemiol 2014; pii:dyu128.
28. Trujillo AA, McCaustland KA, Zheng DP, et al. Use of TaqMan realtime reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol 2006; 44:1405–12.
29. Vega E, Barclay L, Gregorius N, Williams K, Lee D, Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis 2011; 17:1389–95.
30. Phillips G, Tam CC, Conti S, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol 2010; 171:1014–22.
31. Van Trang N, Vu HT, Le NT, Huang P, Jiang X, Anh DD. Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children. J Clin Microbiol 2014; 52:1366–74.
32. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022–8.
33. Glaadstone BP, Ramani S, Mukhopadhyya I, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011; 365:337–46.
34. Lopman B, Kang G. In praise of birth cohorts: norovirus infection, disease and immunity. Clin Infect Dis 2013.
35. Fischer Walker CL, Perin J, Arey MJ, Bosch-Pinto C, Black RE. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. BMC Public Health 2012; 12:220.